Objective: To study the clinical features of chronic hepatitis B (CHB) patients with tyrosine-methionine-aspartateaspartate (YMDD) mutation after lamivudine therapy. Methods: This investigation was a retrospective study of 63 CHB patients with YMDD mutation during lamivudine therapy. Clinical data, including period and types of YMDD mutation; hepatitis B virus (HBV) DNA levels and alanine aminotransferase (ALT) levels before and after YMDD mutation were measured. YMDD mutation in the HBV DNA polymerase gene was determined using polymerase chain reaction (PCR) and direct sequencing. HBV DNA quantification was determined using real-time PCR. Relevant serum markers of HBV were measured. The follow-up period was 12 months after YMDD mutation. Results: YMDD mutation occurred 7~44 months (median, 21.5 months) after the start of lamivudine therapy. The majority of the cases (42/63, 66.6%) had YMDD mutants detected between 12 and 24 months. Four types of YMDD mutation were observed in this study, rtL180M/M204V mutation was the predominant type (26/63, 41.3%). A proportion of patients (16/63, 25.4%; 12/63, 19.1%) had higher HBV DNA levels and ALT levels (after mutation vs before mutation), respectively. Conclusion: The majority of patients with YMDD mutants had similar or lower HBV DNA levels and ALT levels compared with baseline values. This subset of patients might have benefited from the continued lamivudine therapy. The patients with increased ALT and HBV DNA levels (breakthrough hepatitis) should benefit from the addition of a newer nucleotide analogue (e.g. adefovir).
INTRODUCTION
Chronic hepatitis B (CHB) remains a major public health problem, affecting more than 350 million people worldwide. Cirrhosis, liver failure, or hepatocellular carcinoma will develop in approximately 15 to 40 percent of infected patients (Ganem and Prince, 2004) . Lamivudine, an oral nucleoside analogue, inhibits HBV replication (de Clercq, 2001; Lai et al., 1997; Marcellin et al., 2004) . It can markedly reduce serum HBV DNA levels and normalize alanine aminotransferase (ALT) levels in association with decreased liver necroinflammatory activity in a majority of patients (Lai et al., 1998) . Continuous treatment with lamivudine may delay clinical progression in patients with CHB and advanced fibrosis or cirrhosis by significantly reducing the incidence of hepatic decompensation and the risk of hepatocellular carcinoma (Liaw et al., 2004; Wands, 2004) . However, the greatest drawback with lamivudine treatment is the emergence of drug-resistant HBV mutants with concomitant rise in ALT, DNA and worsening histology in some patients. This mutation of the tyrosine-methionine-aspartateaspartate (YMDD) motif in the C domain of the HBV DNA polymerase gene has also been associated with flares of liver disease (Dienstag et al., 1999) . The aim of this study was to report the clinical features of CHB patients with YMDD mutation after lamivudine therapy.
MATERIALS AND METHODS

Patients
This investigation was a retrospective study of 63 patients with CHB. These patients were assessed in an inpatient and outpatient setting for the presence of the YMDD mutation during lamivudine therapy in our hospital from April 1999 to May 2005. They were 49 men and 14 women, aged from 7~68 years. Among these patients, 27, 21 and 15 patients, respectively, had CHB history for less than 5 years, 6~10 years and more than 11 years. In addition, 49 cases were HBeAg positive and 14 were HBeAg negative, HBV DNA levels varied from 10 5~1 0 8 .
Each patient was treated with a single oral dose of 100 mg of lamivudine every day. After YMDD mutation, all patients were followed up monthly; the follow-up period was 12 months. Among these patients, 6 patients discontinued lamivudine therapy; instead, they were treated with Chinese herbs at their own request, 57 patients continued lamivudine therapy. After the emergence of breakthrough hepatitis (ALT becoming abnormal after a period of ALT normalization and re-elevation of HBV-DNA levels after YMDD mutation), 27 patients received lamivudine (100 mg/d) and adefovir dipivoxil (10 mg/d) in combination for 12 months and 6 patients received lamivudine (100 mg/d) and Chinese herbs in combination. Another 24 patients without breakthrough hepatitis continued lamivudine monotherapy (Fig.1 ).
Polymerase chain reactions and sequencing
Mutation in the HBV DNA polymerase gene was determined using polymerase chain reaction (PCR) and direct sequencing. Briefly, DNA was extracted from sera using a QIA Amp DNA blood kit (Qiagene, Inc. Hilden, Germany) and then amplified using PCR. 
Real-time fluorescence PCR
HBV DNA quantification was determined using real-time PCR. Briefly, HBV DNA was extracted from sera using a QIA Amp DNA blood kit (Qiagene, Inc. Hilden, Germany) and then quantified using real-time PCR. Sense primer was (5′ ATCCTGCTG-CTATGCCTCATCTT 3′) and reverse primer was (5′ ACAGTGGGGGAAAGCCCTACGAA 3′). A fluorogenic probe (5′ R-TGGCTAGTTTACAGTGCC-ATTTG-Q 3′) located between the primers was synthesized by Biosearch Inc. Amplification and detection were done with FTC-2000 detection system (Funglyn Biotech). The 50 ml reaction mixture contained 5 ml of 10×Taqman buffer, 200 nmol/L each dATP, dTTP, dGTP dCTP, 0.5 µmol/L each primer, 0.25 µmol/L of Taqman probe, 0.5 U uracil Relevant serum markers of HBV and biochemical detection HBeAg was determined by radioimmunoassay (RIA) diagnostic kits (Wei Fang 3V Biotechnology, Wei Fang, China). ALT measurements were carried at the Centre of Clinical Laboratory, on a computerised automatic multi-analyser Hitachi 7600 (Hitachi Limited, Japan).
RESULTS
Occurrence of YMDD mutation
YMDD mutant occurred 8~44 months (median, 21.5 months) after the commencement of lamivudine therapy. Among them, 8 cases (8/63, 12.7%) had YMDD mutant less than 12 months; 42 cases (42/63, 66.6%) 12~24 months and 13 cases (13/63, 20.7%) more than 24 months.
Types of YMDD mutation
Among the 63 patients, 26 patients (26/63, 41.3%) had rtL180M/M204V mutation, 14/63 (22.2%) had rtL180M/M204I mutation and 18/63 (28.6%) had rtM204I mutation, respectively. There were also 5/63 (7.9%) who had only the rtL180M mutation. However, no YMDD mutants were found in these patients before the start of lamivudine therapy.
HBV DNA levels before lamivudine therapy and after YMDD mutation
Before lamivudine therapy, the HBV DNA levels of the 63 patients were as follows: (10 , 2 cases, 3.2%); (10 9 , 1 case, 1.6%) (Fig.2) .
Among the 63 patients, 17 patients (17/63, 27.0%) had similar HBV DNA levels (after mutation vs before therapy); 30 patients (30/63, 47.6%) had lower HBV DNA levels (after mutation vs before therapy) and 16 patients (16/63, 25.4%) had higher HBV DNA levels (after mutation vs before therapy), respectively (Fig.3) .
ALT levels before lamivudine therapy and after YMDD mutation
Before lamivudine therapy, the ALT levels of the 63 patients were as follows: (<2 upper limit of the normal range (ULN), 17 cases, 27.0%); (2~5 ULN, 41 cases, 65.1%); (6~10 ULN, 5 cases, 7.9%); (>10 ULN, 0 case, 0.0%).
After YMDD mutation, the ALT levels of the 63 patients were as follows: (<2 ULN, 30 cases, 47.6%); (2~5 ULN, 21 cases, 33.4%); (6~10 ULN, 6 cases, 9.5%); (>10 ULN, 6 cases, 9.5%) (Fig.4) . Among the 63 patients, 30 patients (30/63; 47.6%) had similar ALT levels (after mutation vs before therapy); 21 patients (21/63; 33.3%) had lower ALT levels (after mutation vs before therapy) and 12 patients (12/63; 19.1%) had higher ALT levels (after mutation vs before therapy), respectively (Fig.5) .
Results after retreatment
Twenty-seven patients received lamivudine (100 mg/d) and adefovir dipivoxil (10 mg/d) in combination for 12 months after the emergence of breakthrough hepatitis during continuous lamivudine therapy. The mean viral load had decreased by 2 log at least, ALT levels were all less than 2 ULN. There were no toxic side effects due to adefovir treatment. However, there were no significant changes in the levels of HBV DNA and ALT observed in other 57 patients including 6 patients treated with lamivudine and Chinese herbs in combination, 24 patients continuing lamivudine monotherapy and 6 patients treated with Chinese herbs only. DISCUSSION CHB can be treated with a nucleoside analogue, lamivudine (2′3′-dideoxy-3′-thiacytidine). In the short term, substantial inhibition of HBV replication can be achieved. The risk of developing lamivudine resistance increases with the duration of therapy. In a study from Asia, genotypic resistance increased from 14% in year 1 to 38%, 49%, 66%, and 69% after 2, 3, 4, and 5 years, respectively, of treatment (Guan et al., 2001) . Resistance is associated with mutations in the highly conserved YMDD motif (codons 203~206 of the reverse transcriptase (rt)), which is part of the catalytic site of the HBV polymerase (Allen et al., 1998; Chayama et al., 1998) . These resistant HBV strains revealed isoleucine (I) or valine (V) substitutions instead of methionine (M) in the YMDD motif of the RNA-dependent DNA polymerase. The same changes were also observed in lamivudine-resistant human immunodeficiency virus (HIV). Recently, methionine to serine (M204S) in YMDD motif was reported (Bozdayi et al., 2004) . These changes are associated frequently with other changes in the amino acid 180 (leucine to methionine) (Melegari et al., 1998) . The clinical course of hepatitis B in patients with lamivudine-resistant mutants is variable and the long-term outcome remains to be determined. In some patients, emergence of lamivudine-resistant mutants may be accompanied by acute exacerbations of liver disease and rarely hepatic decompensation (Bartholomew et al., 1997; Dienstag et al., 2003; Liaw et al., 1999; Tipples et al., 1996) .
In this study, our results indicated that YMDD mutants occurred 8~44 months (median, 21.5 months) after the commencement of lamivudine therapy. Most of the cases (42/63, 66.6%) developed YMDD mutants between 12 and 24 months.
Our results also indicated that four types of YMDD mutation occurred in this study, L180M/ M204V mutation was the predominant type (26/63, 41.3%). The results were in accordance with other research group's reports (Pillay et al., 1998) .
HBV DNA and ALT levels determined after YMDD mutations were similar or lower than before these mutations. A minority of patients had higher HBV DNA levels (16/63, 25.4%) or ALT levels (12/63, 19.1%) after mutation. This result indicated that despite resistance to lamivudine, some patients with YMDD mutants had significantly lower HBV DNA and ALT levels compared with baseline values. This might have resulted from the decreased replication efficiency of the mutants (Liaw et al., 2000; Melegari et al., 1998; Ono-Nita et al., 1999) .
For patients with confirmed lamivudine resistance, the options from AASLD Practice Guideline include continuing lamivudine treatment as long as it benefits the patient (based on clinical assessment, ALT, and HBV DNA levels) is maintained; discontinuing treatment and monitoring for hepatitis flares; or switching to other antiviral agents such as adefovir, that are effective in suppressing lamivudine-resistant HBV (Lok and McMahon, 2004) . Recently, a study (Chen et al., 2004) showed that patients who discontinued lamivudine therapy had an increased frequency of flare-ups and higher ALT peaks than those who continued therapy for 4 months post breakthrough. Therefore, it is recommended that patients should be followed up carefully once YMDD mutants appear, especially for those with hepatic decompensation at the onset of biochemical breakthrough of YMDD mutants. They could benefit from newer nucleotide analogue (e.g. adefovir) to combat HBV mutants. Our follow-up study also demonstrated the role adefovir plays in treating patients with YMDD mutation. More samples are needed for further study.
